Muscle Hypotonia
Muscle Hypotonia
Explore linked clinical trials. Standard reference: MESH:M001423813 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Aprepitant for the Treatment of CLIFAHDD | Channelopathies, Disease Attributes, Dyskinesias, Facies, Muscle Hypotonia, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, atactic disorder, non-human animal, communication disorder, congenital contractures of the limbs and face, hypotonia, and developmental delay, disease, learning disability, nervous system disorder, neurodevelopmental disorder, psychiatric disorder | Recruiting | Early phase 1 | 2026-10-05 | NCT07845825 | |
| Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Embolism and Thrombosis, Muscle Hypotonia, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, congenital disorder of glycosylation, endocrine system disorder, glucose metabolism disease, hereditary disease, hypoglycemia, hypothyroidism, inborn carbohydrate metabolic disorder, inborn errors of metabolism, intellectual disability, metabolic disease, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, thrombotic disease, thyroid gland disorder, vascular disorder | Recruiting | Not stated | 2026-10-02 | NCT02089789 | |
| Efficacy and Safety of HRS-9190 in General Anesthesia | Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Enrolling by invitation | Phase 3 | 2026-09-09 | NCT07733245 | |
| The Impact of Ventilator Synchrony on Muscle Relaxant Consumption and Surgeon Satisfaction During Laparoscopic Cholecystectomy. | Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Not yet recruiting | Not applicable | 2026-06-15 | NCT07647770 | |
| The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Muscle Hypotonia, Neoplasms by Site, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, nervous system disorder, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-03-09 | NCT03808077 | |
| Long-term Evaluation of Nasopharyngeal Airway in Hypotonia | Abnormalities, Multiple, Airway Obstruction, Apnea, Brain Damage, Chronic, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Dyspnea, Dyssomnias, Muscle Hypotonia, Nasal Obstruction, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Signs and Symptoms, Respiratory, Sleep Disorders, Intrinsic, brain disorder, central nervous system disorder, cerebral palsy, chromosomal disorder, hereditary disease, intellectual disability, nasal disorder, nervous system disorder, obstructive sleep apnea syndrome, otorhinolaryngologic disease, respiratory failure, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Enrolling by invitation | Not applicable | 2025-12-02 | NCT06614582 | |
| Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation | Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Not yet recruiting | Phase 4 | 2025-11-25 | NCT07168252 | |
| Test of Aquatic Mobility of SMA Infants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinal Muscular Atrophies of Childhood, Spinal Muscular Atrophy Type I, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Not applicable | 2025-11-21 | NCT06152302 | |
| Longitudinal Study of Neurogenetic Disorders | Muscle Hypertonia, Muscle Hypotonia, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autism spectrum disorder, communication disorder, intellectual disability, learning disability, nervous system disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, visual epilepsy | Recruiting | Not stated | 2025-10-27 | NCT03492060 | |
| The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio | Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Not stated | 2025-03-27 | NCT06899048 | |
| Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy | Muscle Hypotonia, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Not yet recruiting | Not applicable | 2024-11-29 | NCT06709066 | |
| The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA) | Arrhythmias, Cardiac, Chemically-Induced Disorders, Chronic Pain, Drug-Related Side Effects and Adverse Reactions, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Muscle Hypotonia, Myotoxicity, Neurologic Manifestations, Neuromuscular Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Succinylcholine Sensitivity, Urogenital Diseases, acute kidney injury, butyrylcholinesterase deficiency, cardiovascular disorder, heart disorder, injury, kidney disorder, kidney failure, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, radiation injury, urinary system disorder | Recruiting | Not applicable | 2024-11-27 | NCT06707532 | |
| Register for Patients With Thyroid Hormone Resistance. | Allan-Herndon-Dudley syndrome, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Dyskinesias, Malformations of Cortical Development, Group I, Muscle Hypotonia, Musculoskeletal Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system malformation, cerebral cortical dysplasia, communication disorder, dystonic disorder, endocrine system disorder, hyperthyroxinemia, hypothyroidism, intellectual disability, learning disability, microcephaly, musculoskeletal system disorder, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, thyroid gland disorder, thyroid hormone resistance syndrome, visual epilepsy | Recruiting | Not stated | 2024-08-22 | NCT06566066 |